Bioequivalency Study of Zolpidem Tartrate Under Fasting Conditions
Status: | Completed |
---|---|
Conditions: | Insomnia Sleep Studies |
Therapuetic Areas: | Psychiatry / Psychology |
Healthy: | No |
Age Range: | 18 - 45 |
Updated: | 1/25/2018 |
Start Date: | March 2004 |
End Date: | March 2004 |
A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zolpidem Tartrate Tablets 10 MG Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Zolpidem
Tablets, 10 mg, to Ambien® Tablets, 10 mg (Sanofi-Synthelabo Inc.) under fasting conditions
using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
Tablets, 10 mg, to Ambien® Tablets, 10 mg (Sanofi-Synthelabo Inc.) under fasting conditions
using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical
history, or clinical laboratory results during screening.
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to Zolpidem or any comparable or similar
product.
We found this trial at
1
site
Click here to add this to my saved trials